Elevance Health, Inc. (NYSE:ELV) Shares Bought by Diversified Trust Co

Diversified Trust Co lifted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 13.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,576 shares of the company’s stock after acquiring an additional 2,725 shares during the quarter. Diversified Trust Co’s holdings in Elevance Health were worth $8,328,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Raelipskie Partnership purchased a new stake in Elevance Health during the 3rd quarter worth approximately $26,000. PSI Advisors LLC bought a new stake in shares of Elevance Health in the third quarter worth $27,000. Strategic Financial Concepts LLC acquired a new stake in Elevance Health in the second quarter valued at $30,000. Eastern Bank bought a new position in Elevance Health during the 3rd quarter valued at $31,000. Finally, Dunhill Financial LLC boosted its stake in Elevance Health by 57.8% during the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock valued at $37,000 after acquiring an additional 26 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Activity

In other Elevance Health news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $432.14, for a total value of $3,205,182.38. Following the sale, the executive vice president now directly owns 8,423 shares in the company, valued at $3,639,915.22. This trade represents a 46.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.35% of the stock is currently owned by insiders.

Elevance Health Stock Performance

ELV stock traded up $1.04 during trading on Tuesday, reaching $380.69. 290,718 shares of the company’s stock were exchanged, compared to its average volume of 1,153,423. The firm has a market cap of $88.29 billion, a PE ratio of 13.88, a P/E/G ratio of 1.15 and a beta of 0.84. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56. Elevance Health, Inc. has a 1-year low of $362.21 and a 1-year high of $567.26. The company’s fifty day moving average price is $393.67 and its 200-day moving average price is $475.68.

Elevance Health (NYSE:ELV) last announced its earnings results on Thursday, October 17th. The company reported $8.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.66 by ($1.29). The company had revenue of $44.72 billion during the quarter, compared to the consensus estimate of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.99 EPS. On average, research analysts expect that Elevance Health, Inc. will post 32.96 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 20th. Stockholders of record on Thursday, December 5th were issued a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.71%. The ex-dividend date of this dividend was Thursday, December 5th. Elevance Health’s dividend payout ratio is 23.77%.

Wall Street Analyst Weigh In

ELV has been the topic of a number of recent analyst reports. TD Cowen cut their target price on shares of Elevance Health from $589.00 to $484.00 and set a “buy” rating on the stock in a research note on Monday, October 21st. Argus downgraded Elevance Health from a “buy” rating to a “hold” rating in a report on Friday, October 18th. Wells Fargo & Company lowered their price target on Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a report on Monday, November 4th. StockNews.com lowered Elevance Health from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Mizuho lowered their target price on shares of Elevance Health from $585.00 to $505.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $536.53.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.